A carregar...

Advertisement

Incyte Q1 Results Top Estimates

RTTNews | 1189 dias atrás

Incyte Q1 Results Top Estimates

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported net income of $161.43 million or $0.72 per share for the first quarter, up from $149.46 million or $0.67 per share in the prior-year quarter.

Excluding items, adjusted net income for the quarter was $1.01 per share, compared to $0.80 per share in the year-ago quarter.

Total revenues for the quarter rose 29 percent to $911.40 million from $705.71 million in the same quarter last year.

On average, analysts polled by Thomson Reuters expected the company to report earnings of $0.76 per share on revenues of $818.49 million for the quarter. Analysts' estimates typically exclude special items.

Looking ahead to fiscal 2022, Incyte now projects Jakafi net product revenue in a range of $2.36 billion to $2.40 billion. Other Hematology/Oncology net product revenues are projected between $210 million and $240 million.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Etiquetas: INCY

read more

Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

Incyte Q4 Adj EPS Misses Estimates, But Revenues Top

Incyte Corp. (INCY) on Tuesday reported net income of $201.10 million or $0.89 per share for the fourth quarter, sharply higher than $28.46 million or $0.13 per share in the prior-year quarter.

RTTNews | 629 dias atrás

Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Says FDA Issued CRL For Ruxolitinib Extended-release Tablets

Incyte Corp. (INCY) announced Friday that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, for once-daily (QD) use in the treatment of certain types of myelofibrosis (MF), polycythemia vera (PV) and graft-versus-host disease (GVHD).

RTTNews | 955 dias atrás

Fed's Hawkish Guidance Lifts Dollar

Fed's Hawkish Guidance Lifts Dollar

A drastic reduction in Fed rate cut hopes in the aftermath of the hawkish forward guidance by Chair Jerome Powell boosted the U.S. Dollar during the week ended October 31.

RTTNews | 1 h 11 min atrás

CAC Modestly Higher; Renault Up After Announcing Stake Sale In Brazil Venture

CAC Modestly Higher; Renault Up After Announcing Stake Sale In Brazil Venture

French stocks are modestly higher on Monday with investors continuing to digest the latest quarterly earnings, and reacting to the data showing an improvement in the nation's manufacturing activity in the month of October.

RTTNews | 1 h 21 min atrás

DAX Rises Over 1% As Banks, Auto Stocks Rally

DAX Rises Over 1% As Banks, Auto Stocks Rally

The German market is up firmly in positive territory on Monday, led by gains in automobile and banking sectors. The undertone remains firm with investors continuing to assess recent earnings announcements, and looking ahead to a fresh batch of economic data from the region and the U.S.

RTTNews | 1 h 54 min atrás

Euro Falls Against Most Majors

Euro Falls Against Most Majors

The euro weakened against other major currencies in the European session on Monday.

RTTNews | 1 h 56 min atrás

Sensex, Nifty End Choppy Session Marginally Higher

Sensex, Nifty End Choppy Session Marginally Higher

Indian shares ended little changed on Monday after a choppy session. Caution prevailed ahead of a big week for earnings, with around 200 prominent companies scheduled to report their quarterly earnings results.

RTTNews | 2 h 37 min atrás

Swiss Franc Falls Amid Disappointing Swiss CPI Data

Swiss Franc Falls Amid Disappointing Swiss CPI Data

The Swiss franc weakened against other major currencies in the European session on Monday, after data showed that Switzerland's consumer price inflation slowed unexpectedly in October after remaining stable in the previous two months.

RTTNews | 4 h 2 min atrás

Termos | Privacidade | Mapa do SIte | Site Map Calendar

© 2025 Myfxbook Ltd Todos os Direitos Reservados.

AVISO DE ALTO RISCO: A negociação em moeda estrangeira comporta um alto nível de risco que pode não ser adequado para todos os investidores. A vantagem cria risco adicional e exposição a perdas. Antes de decidir negociar em moeda estrangeira, considere cuidadosamente os seus objetivos de investimento, nível de experiência e tolerância ao risco. Pode perder parte ou todo o seu investimento inicial. Não invista dinheiro que não possa perder. Eduque-se sobre os riscos associados à negociação em moeda estrangeira e procure aconselhamento de um consultor financeiro ou fiscal independente se tiver alguma dúvida. Quaisquer dados e informações são fornecidos apenas para fins informativos e não se destinam a fins comerciais ou de consultoria. O desempenho anterior não é indicativo de resultados futuros.